Back to top

Tale of the Tape

Novo Nordisk Enters Oversold Territory
June 25, 2013


Trades from $3

Novo Nordisk ’s (NVO - Analyst Report) share price has entered into oversold territory with an RSI value of 23.85. The Zacks Consensus Estimate on Novo Nordisk’s earnings for the full year period have moved higher by 16 cents over the past two months to $8.27 per share. Currently, Novo Nordisk is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (NVO - Analyst Report) after its recent drop.